2024 年度募集资金存放与使用情况的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为博 济医药科技股份有限公司（以下简称"博济医药"或"公司"）的保荐机构， 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关法律法规及规范性文件的要 求，对博济医药 2024 年度募集资金存放与使用情况进行了核查，具体情况如下： 一、募集资金基本情况 （一）实际募集金额及资金到位情况 广发证券股份有限公司关于博济医药科技股份有限公司 （一）募集资金的管理情况 为了规范募集资金的管理和使用，保护投资者权益，公司依照《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关法律、法规的规定，结合公司的实际情况，制 定了《募集资金管理制度》，对募集资金的存储、使用、用途变更及监督管理作 出了明确规定。 公司对募集资金实行专户存储，并对募集资金的使用执行严格的审批程序， 以保证专款专用。 2021 年，公司 ...

博济医药科技股份有限公司 2024 年度审计报告 司农审字[2025]24008270037 号 目 录 | 审计报告………………………………………………… | 1-6 | | --- | --- | | 合并资产负债表………………………………………… | 1 | | 合并利润表……………………………………………… | 2 | | 合并现金流量表………………………………………… | 3 | | 合并所有者权益变动表………………………………… | 4-5 | | 母公司资产负债表……………………………………… | 6 | | 母公司利润表…………………………………………… | 7 | | 母公司现金流量表……………………………………… | 8 | | 母公司所有者权益变动表……………………………… | 9-10 | | 财务报表附注…………………………………………… | 11-121 | 1 审 计 报 告 司农审字[2025]24008270037 号 博济医药科技股份有限公司全体股东: 一、审计意见 我们审计了博济医药科技股份有限公司（以下简称"博济医药"）财务报表，包 括 2024 年 12 月 31 日 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥138,861,747.84, a decrease of 17.06% compared to ¥167,424,382.67 in the same period last year[5] - The net profit attributable to shareholders was ¥3,900,579.72, down 76.38% from ¥16,513,092.18 year-on-year[5] - The basic earnings per share decreased to ¥0.0102, down 76.39% from ¥0.0432 in the same period last year[5] - The total comprehensive income for the period was ¥4,597,792.32, a decrease of 74.20% compared to ¥17,821,249.12 in the previous year[12] - Operating profit for the current period is CNY 3,903,457.70, a decline of 76.5% from CNY 16,614,526.52 in the previous period[26] - Net profit for the current period is CNY 3,843,087.85, down 77.0% from CNY 16,631,692.07 in the previous period[26] - The net profit attributable to the parent company was 3,900,579.72 yuan, a decrease from 16,513,092.18 yuan in the previous period, representing a decline of approximately 76.4%[27] - The total comprehensive income attributable to the parent company was 3,818,213.24 yuan, down from 17,076,703.66 yuan, indicating a decrease of about 77.7%[27] Cash Flow - The net cash flow from operating activities improved significantly to ¥8,828,695.62, compared to a negative cash flow of ¥15,764,811.36 in the previous year, representing a 156.00% increase[5] - Cash inflows from operating activities totaled 189,364,292.08 yuan, compared to 142,260,961.86 yuan in the prior period, reflecting an increase of approximately 33.2%[29] - Cash outflows from operating activities were 180,535,596.46 yuan, up from 158,025,773.22 yuan, marking an increase of about 14.3%[30] - The net cash flow from investing activities was -130,073,402.19 yuan, slightly improved from -153,727,515.94 yuan in the previous period[30] - The net cash flow from financing activities was 4,518,319.16 yuan, compared to a net outflow of 8,523,943.30 yuan in the prior period, indicating a turnaround[30] - The ending cash and cash equivalents balance was 151,790,383.34 yuan, down from 217,196,523.19 yuan, a decrease of approximately 30.1%[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,491,435,459.66, reflecting a 2.82% increase from ¥1,450,592,225.50 at the end of the previous year[5] - Total current assets increased to CNY 823,520,451.16 from CNY 780,278,696.05, representing a growth of 5.0%[24] - Total non-current assets decreased slightly to CNY 667,915,008.50 from CNY 670,313,529.45, a decline of 0.4%[25] - Total liabilities increased to CNY 477,087,563.67 from CNY 448,838,881.46, an increase of 6.3%[25] - Total equity attributable to shareholders increased to CNY 985,275,784.42 from CNY 973,381,474.22, a growth of 1.0%[26] - Cash and cash equivalents decreased to CNY 153,365,620.33 from CNY 270,133,867.18, a decline of 43.2%[24] - Inventory increased to CNY 220,311,229.03 from CNY 189,485,440.64, an increase of 16.3%[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 26,693[15] - The largest shareholder, Wang Tingchun, holds 30.97% of the shares, amounting to 118,674,370 shares, with 89,005,777 shares pledged[16] - The top 10 shareholders hold a total of 89,005,777 shares, with no changes in the number of restricted shares during the period[19] - The total number of restricted shares at the end of the period was 105,113,676 shares, with 1,422,750 shares released during the period[19] - The company has a repurchase special account holding 2,667,000 shares, accounting for 0.70% of the total share capital[19] - The company’s major shareholder, Wang Tingchun, holds 29,668,593 shares, representing a significant portion of the total shares[18] - The company’s major shareholder, Zhao Lingli, holds 4,804,905 shares, indicating strong insider ownership[18] - The company has established a unified action relationship among certain shareholders, enhancing governance and decision-making[18] Research and Development - The company successfully passed the GLP certification review and received the new "Drug GLP Certification" with a total of 8 certification qualifications[20] - The company signed a technology transfer contract with Shaanxi Panlong Pharmaceutical Group, transferring the technology for "Glucosamine Sulfate Capsules" for a total fee of RMB 4.5 million[20] - The company's subsidiary, Huasheng Pharmaceutical, received approval for the listing application of "Sodium Sulfate" from the National Medical Products Administration[21] - In the first quarter of 2025, the company and its subsidiaries obtained seven invention patents from the National Intellectual Property Administration[21] Return on Equity - The weighted average return on equity was 0.40%, a decline of 1.32% from 1.72% in the previous year[5]

Financial Performance - Boji Medical Technology Co., Ltd. reported a revenue of RMB 500 million for the fiscal year 2024, representing a 20% increase compared to RMB 416.67 million in 2023[20]. - The company's operating revenue for 2024 reached ¥742,019,124.54, representing a 33.50% increase compared to ¥555,832,418.60 in 2023[5]. - The net profit attributable to shareholders for 2024 was ¥28,776,806.52, an 18.23% increase from ¥24,339,436.55 in 2023[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 92.71% to ¥19,304,628.89 from ¥10,017,432.95 in 2023[5]. - The company anticipates a net profit margin of 10% for 2024, compared to 8% in 2023, driven by operational efficiencies[20]. - The company reported a total investment of ¥44,125,000.00 during the reporting period, representing a substantial increase of 186.48% compared to ¥15,402,616.00 in the previous year[85]. - The company achieved a gross profit margin of 64.64% for the reported period[93]. Dividend Distribution - The company plans to distribute a cash dividend of 0.12 yuan per 10 shares to all shareholders, based on a total of 380,503,928 shares[8]. - The cash dividend represents 100% of the total distributable profit of RMB 28,776,806.52 for the year[154]. - For the year 2024, the company proposes a cash dividend of RMB 0.12 per 10 shares, with a total expected payout of RMB 4,566,047.14[156]. Business Expansion and Strategy - The company aims to expand its market presence by launching three new drug candidates in 2024, targeting a market size of approximately RMB 1 billion[20]. - The company is expanding its business into preclinical research and CDMO services, facing potential risks due to competition and lack of experience in these areas[8]. - The company is pursuing strategic acquisitions to bolster its capabilities, with a target of completing two acquisitions by the end of 2024[20]. - The company is focused on enhancing its digital health solutions, aiming for a 50% increase in user engagement through its online platforms in 2024[20]. - The company is committed to increasing its market share in the CDMO sector by improving order fulfillment capabilities and reducing delivery cycles, targeting rapid revenue growth from commercialized products[108]. Research and Development - The company has allocated RMB 100 million for research and development of new technologies and products in 2024, a 25% increase from RMB 80 million in 2023[20]. - The company has developed a one-stop service platform for preclinical research, significantly enhancing its capabilities in pharmacology and toxicology evaluations[49]. - The company has achieved GLP certification for its non-clinical evaluation services, covering various therapeutic areas, including cardiovascular and oncology drugs[52]. - The company is developing a long-acting nano-crystal technology platform aimed at improving drug delivery and reducing administration frequency, which is anticipated to create new business growth points[71]. - The company has completed the development of a new formulation of berberine for children, which is easier to administer[73]. Risk Management - The company acknowledges the risk of contract execution delays due to the complex nature of new drug development, which may lead to increased operational costs[5]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with its expanding operational scale and business scope[8]. - The company recognizes the volatility of drug approval policies in China, which could impact its R&D investments and revenue[4]. - The company has established specific responsibility-sharing models in contracts to address potential delays and associated penalties[6]. Market Competition - The company faces increased market competition from domestic CRO companies, necessitating higher marketing and service standards[7]. - The Chinese CRO industry is expected to maintain a CAGR of 14%-16% from 2024 to 2026, with the market size projected to reach ¥478 billion in 2024[32]. - The company anticipates strong demand for outsourced clinical research services due to increasing complexity in drug development and stricter regulatory requirements[33]. Governance and Compliance - The company maintains independence from its controlling shareholder in terms of business, personnel, assets, and finance[118]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[114]. - The company has a dedicated financial department and independent financial decision-making capabilities[118]. - The company has not faced any disciplinary actions from regulatory bodies regarding internal control issues during the reporting period[117]. - The company ensures timely and accurate information disclosure through designated platforms and publications[115]. Environmental Responsibility - The company has obtained a wastewater discharge permit valid until October 31, 2027[187]. - The wastewater treatment facility has a capacity of 120m³/d and employs a "flocculation sedimentation + iron-carbon micro-electrolysis" process[189]. - The company reported a total wastewater discharge of 0.33 tons for CODcr, which is below the regulatory limit of 0.412 tons per annum[188]. - The company has established solid waste management records to ensure compliance with environmental regulations[192]. Employee Management - The company had a total of 1,169 employees at the end of the reporting period, with 888 being technical personnel, representing approximately 76% of the workforce[148]. - The company has a comprehensive training system that includes various training categories, ensuring continuous development of employee skills and capabilities[151]. - The company has implemented a differentiated compensation policy based on department, position, and job nature, aiming for performance-oriented salary management[150]. Future Outlook - The company plans to continue expanding its market presence and enhancing product development strategies[1]. - Future outlook includes potential adjustments in management structure following the resignation of certain executives in 2025[140]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[134].

博济医药（300404）公告，2025年第一季度营业收入1.39亿元，同比下降17.06%。净利润390.06万元， 同比下降76.38%。 ...

Core Insights - Boji Pharmaceutical's stock closed at 9.15 yuan, up 2.58%, with a rolling PE ratio of 78.60 times and a total market capitalization of 3.505 billion yuan [1] - The average PE ratio for the medical services industry is 46.70 times, with a median of 48.76 times, placing Boji Pharmaceutical at the 34th position in the industry ranking [1] - As of September 30, 2024, the number of shareholders for Boji Pharmaceutical is 22,995, a decrease of 4,424 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Boji Pharmaceutical Co., Ltd. primarily provides comprehensive "one-stop" CRO services for domestic and international pharmaceutical companies and research institutions, including clinical research services, preclinical research services, CDMO services, consulting services, independent preclinical R&D, and technology transfer services [1] - The company has received several accolades, including being ranked 8th in the "Top 20 Chinese Pharmaceutical CRO Companies 2024," recognized in the "Top 50 Chinese Pharmaceutical R&D Companies 2023," and awarded the "Excellence Achievement Award" for being a high-tech enterprise for 15 consecutive years [1] Financial Performance - In the latest quarterly report for 2024, Boji Pharmaceutical achieved a revenue of 555.6 million yuan, representing a year-on-year increase of 55.01%, and a net profit of 43.2778 million yuan, reflecting a year-on-year growth of 87.98%, with a gross profit margin of 32.19% [1]

2024 年 8 月 23 日，博济医药科技股份有限公司（以下简称"公司"）召开 第五届董事会第十次会议和第五届监事会第十次会议，审议通过了《关于使用暂 时闲置募集资金进行现金管理的议案》，同意公司及子公司使用不超过人民币 0.6 亿元（含）闲置募集资金进行现金管理，有效期自董事会审议通过之日起 12 个 月内，在前述额度和期限范围内可循环滚动使用。具体内容详见公司于 2024 年 8 月 27 日在巨潮资讯网（http://www.cninfo.com.cn/）上发布的《关于使用暂时闲 置募集资金进行现金管理的公告》（公告编号：2024-087）。 近日，公司全资子公司深圳博瑞医药科技有限公司（以下简称"深圳博瑞"） 在授权范围内使用闲置募集资金购买的理财产品已到期赎回。现就有关进展情况 公告如下： 证券代码：300404 证券简称：博济医药 公告编号：2025-018 博济医药科技股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | | | 中国工商银 | 中国工商银行挂钩汇率法 | | | ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Boji Pharmaceutical, which has a current stock price of 9.1 yuan and a rolling PE ratio of 78.17 times, significantly higher than the industry average of 46.29 times [1][2] - Boji Pharmaceutical's total market capitalization is 3.486 billion yuan, ranking 35th in the medical services industry based on PE ratio [1][2] - As of the third quarter of 2024, 51 institutions hold shares in Boji Pharmaceutical, with a total of 2.6617 million shares valued at 0.023 billion yuan [1] Group 2 - The company specializes in providing comprehensive CRO services for pharmaceutical companies and research institutions, including clinical research, preclinical research, CDMO services, and technology transfer [1] - Boji Pharmaceutical has received several accolades, including being ranked 8th among the top 20 CRO companies in China for 2024 and recognized as one of the top 50 pharmaceutical R&D companies in 2023 [1] - The latest financial results for the third quarter of 2024 show that the company achieved a revenue of 0.556 billion yuan, representing a year-on-year increase of 55.01%, and a net profit of 43.2778 million yuan, up 87.98% year-on-year, with a gross profit margin of 32.19% [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300404 证券简称：博济医药 公告编号：2025-017 博济医药科技股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的公告 1 2024 年 8 月 23 日，博济医药科技股份有限公司（以下简称"公司"）召开 第五届董事会第十次会议和第五届监事会第十次会议，审议通过了《关于使用暂 时闲置募集资金进行现金管理的议案》，同意公司及子公司使用不超过人民币 0.6 亿元（含）闲置募集资金进行现金管理，有效期自董事会审议通过之日起 12 个 月内，在前述额度和期限范围内可循环滚动使用。具体内容详见公司于 2024 年 8 月 27 日在巨潮资讯网（http://www.cninfo.com.cn/）上发布的《关于使用暂时闲 置募集资金进行现金管理的公告》（公告编号：2024-087）。 近日，公司在授权范围内使用闲置募集资金购买的理财产品已到期赎回。现 就有关进展情况公告如下： 二、 截至本公告日前十二个月内使用闲置募集资金购买理财产品的情况 | 序 | 委托方 | 受托方 | 产品名称 | 产品 ...

专利申请日：2024 年 07 月 29 日 授权公告日：2025 年 04 月 08 日 本发明属于生物医学检测技术领域，具体涉及一种检测人源细胞在动物体内 分布的方法及检测产品。本发明公开的检测方法简单快速、特异性好、灵敏度高、 检测范围宽，可用来示踪动物体内植入的人源细胞的定向分布，可以实现短时间 内处理大量的样本，为干细胞产品的遴选提供数据支持。 证券代码：300404 证券简称：博济医药 公告编号：2025-016 博济医药科技股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，博济医药科技股份有限公司（以下简称"公司"）获得国家知识产权 局颁发的一项发明专利证书，具体情况如下： 发明名称：一种检测人源细胞在动物体内分布的方法及检测产品 专 利权人 ：博济医药科技股份有限公司 证书号：第 7859104 号 专利号：ZL 2024 1 1018741.2 该专利的获得对公司经营业绩不会产生重大影响，但有利于公司的技术创新， 完善知识产权保护体系，充分发挥公司的自主知识产权优势，形成持续创新机制， 提升公 ...